Patents by Inventor Candelaria Gomez-Manzano

Candelaria Gomez-Manzano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adenoviruses expressing heterologous tumor-associated antigens
    Patent number: 11155599
    Abstract: The present invention is directed to adenoviruses for use in cancer therapy which comprise one or more heterologous nucleic acid sequences encoding a tumor antigen, whereby the adenovirus expresses the tumor antigen(s) on its surface.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: October 26, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Juan Fueyo-Margareto, Candelaria Gomez-Manzano, W. K. Alfred Yung, Victor Krasnykh, Hong Jiang
  • ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S)
    Publication number: 20210301264
    Abstract: Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.
    Type: Application
    Filed: June 11, 2021
    Publication date: September 30, 2021
    Applicants: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Juan Fueyo-Margareto, Candelaria Gomez-Manzano, Charles Conrad, Alfred W.K. Yung, Hong Jiang
  • Adenovirus and immunomodulator combination therapy
    Patent number: 11090344
    Abstract: Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: August 17, 2021
    Assignees: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Juan Fueyo-Margareto, Candelaria Gomez-Manzano, Charles Conrad, W. K. Alfred Yung, Hong Jiang
  • Biomarkers and combination therapies using oncolytic virus and immunomodulation
    Patent number: 11065285
    Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: July 20, 2021
    Assignees: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Charles Conrad, Juan Fueyo-Margareto, Frederick Lang, Jr., Candelaria Gomez-Manzano, W.K. Alfred Yung, Amy Heimberger
  • TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS
    Publication number: 20210213079
    Abstract: The present disclosure involves compositions and methods for treating brain cancers having mutations in the retinoblastoma (Rb) pathway using an oncolytic adenovirus comprising an alteration in the Rb binding site of E1A, and a targeting motif inserted in the Ad fiber protein. The adenovirus is able to kill the tumor cells without harming cells with a wild-type retinoblastoma pathway.
    Type: Application
    Filed: March 5, 2021
    Publication date: July 15, 2021
    Inventors: Juan FUEYO-MARGARETO, Candelaria GOMEZ-MANZANO, Charles CONRAD, Fred LANG, JR., W.K. Alfred YUNG, Frank TUFARO
  • BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION
    Publication number: 20200330533
    Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
    Type: Application
    Filed: June 30, 2020
    Publication date: October 22, 2020
    Inventors: Frank TUFARO, Charles CONRAD, Juan FUEYO-MARGARETO, Frederick LANG, JR., Candelaria GOMEZ-MANZANO, W.K. Alfred YUNG, Amy HEIMBERGER
  • BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION
    Publication number: 20190269744
    Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
    Type: Application
    Filed: March 5, 2019
    Publication date: September 5, 2019
    Inventors: Frank TUFARO, Charles CONRAD, Juan FUEYO-MARGARETO, Frederick LANG, JR., Candelaria GOMEZ-MANZANO, W.K. Alfred YUNG, Amy HEIMBERGER
  • Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
    Patent number: 10391183
    Abstract: A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: August 27, 2019
    Assignees: The UAB Research Foundation, The Board of Regents of the University of Texas System
    Inventors: Juan Fueyo-Margareto, Candelaria Gomez-Manzano, David Curiel
  • ADENOVIRUS AND IMMUNOMODULATOR COMBINATION THERAPY
    Publication number: 20190201462
    Abstract: Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.
    Type: Application
    Filed: May 30, 2017
    Publication date: July 4, 2019
    Inventors: Frank TUFARO, Juan FUEYO-MARGARETO, Candelaria GOMEZ-MANZANO, Charles CONRAD, W.K. Alfred YUNG, Hong JIANG
  • ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S)
    Publication number: 20190093085
    Abstract: Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.
    Type: Application
    Filed: June 27, 2018
    Publication date: March 28, 2019
    Applicants: DNATRIX, INC., THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Juan Fueyo-Margareto, Candelaria Gomez-Manzano, Charles Conrad, Alfred W.K. Yung, Hong Jiang
  • Biomarkers and combination therapies using oncolytic virus and immunomodulation
    Patent number: 10238698
    Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: March 26, 2019
    Assignees: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Charles Conrad, Juan Fueyo-Margareto, Frederick Lang, Jr., Candelaria Gomez-Manzano, W. K. Alfred Yung, Amy Heimberger
  • Oncolytic adenovirus armed with therapeutic genes
    Patent number: 10080774
    Abstract: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: September 25, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Juan Fueyo, Candelaria Gomez-Manzano, W. K. Alfred Yung, Charles A. Conrad, Frederick F. Lang, Jr.
  • Adenovirus Expressing Immune Cell Stimulatory Receptor Agonist(s)
    Publication number: 20160289645
    Abstract: Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy.
    Type: Application
    Filed: November 21, 2014
    Publication date: October 6, 2016
    Applicants: DNATRIX, INC., THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYST EM
    Inventors: Frank TUFARO, Juan FUEYO-MARGARETO, Candelaria GOMEZ-MANZANO, Charles CONRAD, Alfred W.K. YUNG, Hong JIANG
  • ONCOLYTIC ADENOVIRUS ARMED WITH THERAPEUTIC GENES
    Publication number: 20150306160
    Abstract: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
    Type: Application
    Filed: May 4, 2015
    Publication date: October 29, 2015
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Juan FUEYO, Candelaria GOMEZ-MANZANO, W. K. Alfred YUNG, Charles A. CONRAD, Frederick F. LANG, JR.
  • Oncolytic adenovirus armed with therapeutic genes
    Patent number: 9061055
    Abstract: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: June 23, 2015
    Assignee: Board of Regentsm The University of Texas System
    Inventors: Juan Fueyo, Candelaria Gomez-Manzano, W.K. Alfred Yung, Charles A. Conrad, Frederick F. Lang, Jr.
  • ADENOVIRUSES EXPRESSING HETEROLOGOUS TUMOR-ASSOCIATED ANTIGENS
    Publication number: 20140377294
    Abstract: The present invention is directed to adenoviruses for use in cancer therapy which comprise one or more heterologous nucleic acid sequences encoding a tumor antigen, whereby the adenovirus expresses the tumor antigen(s) on its surface.
    Type: Application
    Filed: February 1, 2013
    Publication date: December 25, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Juan Fueyo-Margareto, Candelaria Gomez-Manzano, W.K. Alfred Yung, Victor Krasnykh, Hong Jiang
  • BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION
    Publication number: 20140377221
    Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
    Type: Application
    Filed: January 25, 2013
    Publication date: December 25, 2014
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, DNATRIX INC.
    Inventors: Frank Tufaro, Charles Conrad, Juan Fueyo-Margareto, Frederick Lang, Candelaria Gomez-Manzano, W.K. Alfred Yung, Amy Heimberger
  • INFECTIVITY-ENHANCED CONDITIONALLY-REPLICATIVE ADENOVIRUS AND USES THEREOF
    Publication number: 20140227226
    Abstract: A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.
    Type: Application
    Filed: January 6, 2014
    Publication date: August 14, 2014
    Applicants: The UAB Research Foundation, The Board of Regents of the University of Texas System
    Inventors: Juan FUEYO-MARGARETO, Candelaria GOMEZ-MANZANO, David CURIEL
  • INFECTIVITY-ENHANCED CONDITIONALLY-REPLICATIVE ADENOVIRUS AND USES THEREOF
    Publication number: 20120207711
    Abstract: A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.
    Type: Application
    Filed: April 11, 2012
    Publication date: August 16, 2012
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Juan Fueyo, Candelaria Gomez-Manzano
  • Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
    Patent number: 8168168
    Abstract: A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: May 1, 2012
    Inventors: Juan Fueyo, Candelaria Gomez-Manzano